dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

NorthStar Medical closes $100 million financing with Oberland Capital to expand domestic Mo-99 radioisotope production capacity

Zionexa completes a second $5 million capital raise

SNMMI and ACR collaborate on clinical data registry for nuclear medicine

New PET imaging biomarker could better predict progression of Alzheimer's disease

MILabs installs new E-Class SPECT/CT system to enhance heart failure research at CHFC in Germany

Nordion and BRIT collaborate to bring cobalt-60 from India to global markets

Bruce Power completes harvest of Cobalt-60 that will save lives through cancer treatments

Nordion and Tong Xing expand cobalt-60 supply agreement

Advanced imaging technology predicts cardiovascular risk from inflammation detected in arteries

TRIUMF receives historic investment in 2019 federal budget

Nuclear medicine imaging monitors effectiveness of therapy for melanoma patients

Press releases may be edited for formatting or style
RESTON, Va. – Metastatic melanoma is one of the deadliest skin cancers, so determination of a treatment’s effectiveness is essential but can be tricky. A study featured in the March issue of The Journal of Nuclear Medicine demonstrates that 18F-FDG positron emission tomography/computed tomography (PET/CT) can monitor immunotherapy with ipilimumab, a “checkpoint inhibitor” that allows the immune system to attack cancer cells.

“Checkpoint inhibitor therapy is now a standard therapy for metastatic melanoma,” explains Wolfgang A. Weber, MD, of Technical University Munich, Germany (formerly of Memorial Sloan Kettering Cancer Center). “However, there were concerns about whether FDG PET/CT could be used to monitor tumor response to this immunotherapy, because inflammatory reactions to the immunotherapy may cause false positive findings. The present study shows that tumor response to checkpoint inhibitor therapy with ipilimumab can be assessed accurately by FDG PET after completion of ipilimumab therapy.”

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



Clinical studies have shown that ipilimumab, when compared with chemotherapy, can significantly improve the survival of patients with metastatic melanoma; however, this is true for only 15 to 20 percent of melanoma patients. The ability to accurately assess a patient’s response to ipilimumab therapy would allow physicians to adjust his or her course of treatment for maximum effectiveness.

To overcome the difficulties of assessing tumor response to ipilimumab and other checkpoint inhibitors, the researchers developed new response criteria. These new criteria require confirmation of tumor progression on a follow-up scan.

For this retrospective study, 60 patients with metastatic melanoma received FDG PET/CT scans pre- and post-treatment. Tumor response was assessed by the change in the sum of SULpeak (standard uptake value normalized to lean body mass) of up to 5 lesions (PERCIST5). A second analysis (PERCIST1) was done of the lesion with the highest SULpeak between the baseline and follow-up scan. New lesions on PET that appeared suspicious for metastases were considered progressive metabolic disease. To assess new inflammatory lesions, the team applied their novel immunotherapy-modified PERCIST with a 5-lesion analysis (imPERCIST5). In imPERCIST5, a new lesion on FDG PET/CT is considered progressive disease only if it increases the sum of SULpeak by more than 20%.

The results of the study show that assessment of tumor response to ipilimumab treatment using PERCIST correlated significantly with survival of patients with advanced melanoma. The slight modifications of PERCIST to imPERCIST5 further improved the prognostic value of response assessment by 18F-FDG PET/CT.
  Pages: 1 - 2 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED